Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial

OBJECTIVE: To report the 2‐year efficacy and safety of tocilizumab (TCZ) in patients with polyarticular‐course juvenile idiopathic arthritis (JIA). METHODS: Patients ages 2–17 years with active polyarticular‐course JIA, in whom treatment with methotrexate was unsuccessful, received 16 weeks of open‐...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Rheumatol
Main Authors: Brunner, Hermine I., Ruperto, Nicolino, Zuber, Zbigniew, Cuttica, Rubén, Keltsev, Vladimir, Xavier, Ricardo M., Burgos‐Vargas, Ruben, Penades, Inmaculada Calvo, Silverman, Earl D., Espada, Graciela, Zavaler, Manuel Ferrandiz, Kimura, Yukiko, Duarte, Carolina, Job‐Deslandre, Chantal, Joos, Rik, Douglass, Wendy, Wimalasundera, Sunethra, Bharucha, Kamal N., Wells, Chris, Lovell, Daniel J., Martini, Alberto, de Benedetti, Fabrizio
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Pediatric Rheumatology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7986602/
https://ncbi.nlm.nih.gov/pubmed/32951358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.41528
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados